IP Library Granted Patent US 10,548,893
Granted Patent B2
US 10,548,893 · App. 16/204,582 · Granted Feb 4, 2020

Inhibitors of multidrug resistance transporter P-glycoprotein

Inventors: John G. Wise (Dallas, TX); Pia D. Vogel (Dallas, TX); Frances K. Brewer (Waxahachie, TX); Courtney A. Follit (Dallas, TX)
Assignee: Southern Methodist University
A61K31/5025A61K31/352A61K31/353A61K31/4196A61K31/4525A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,548,893
App. No.
16/204,582
Granted
Feb 4, 2020
Kind
B2
Abstract

The present disclosure provides a method of treating a subject that is resistant to one or more drugs by identifying a subject having one or more drug resistant cells; administering to the subject a pharmaceutically effective amount of an inhibitor compound, and contacting one or more drug resistant cells with the inhibitor compound to reduce the export of the inhibitor compound from the one or more drug resistant tumor cells and to block the transport of drug(s) from the one or more drug resistant cells.

Claims (6)

1. A method of sensitization and re-sensitization of a prostate cancer cell to a chemotherapeutic comprising the steps of:

identifying a subject having one or more cancer cells that express P-glycoprotein in need of sensitization and re-sensitization to one or more chemotherapeutic;

administering to the subject a pharmaceutically effective amount of an inhibitor compound having one of the following structural formulas:

2. The method of claim 1 , wherein the inhibitor compound interacts with one or more ATP binding domain(s) of a P-glycoprotein, or does not bind to drug binding sites on the P-glycoprotein.

3. The method of claim 1 , wherein the prostate cancer cells are multidrug resistant cancer cells or tumor cells or cancer stem cells.

4. The method of claim 1 , further comprising the step of administering one or more chemotherapeutic agents to the subject.

Assignments (2)
CONFIRMATORY LICENSE Recorded Nov 4, 2022
From: SOUTHERN METHODIST UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061883/0603 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2018
From: WISE, JOHN G.; VOGEL, PIA D.; BREWER, FRANCES K.; FOLLIT, COURTNEY A.
To: SOUTHERN METHODIST UNIVERSITY
Reel/Frame 047626/0850 →
Continuity (4)
Continuation 15406036 · Jan 13, 2017
Continuation 14598022 · Jan 15, 2015
Provisional Application 61927767 · Jan 15, 2014
Related Publication 20190091223A1 · Mar 28, 2019